Laval, Canada – (BUSINESSWIRE) – April 13, 2023 – BIOQuébec, CQDM, Fonds de solidarité FTQ and adMare BioInnovations, co-organizers of Sweet Biopharma Day, are pleased to announce that Epitopea, represented by Steven Klein, is the winner of the 2023 edition.
Read MoreLaval, April 13, 2023 – BIOQuébec’s board of directors is proud to announce that Benoit Larose has been named its executive director, effective May 1, 2023.
Read MoreWe would like to notify you that as of February 17, 2023, Emmanuelle Toussaint no longer holds the position of Executive Director at BIOQuébec. BIOQuébec is very appreciative of the tremendous work done by Emmanuelle and grateful for her dedication and involvement over the past six months. We wish her continued success in her professional journey.
Read MoreOn December 10th, 2021, BIOQuébec and other players in the life sciences industry in Quebec sent several federal elected officials their serious concerns regarding the coming into force of the PMPRB reform. As leading representatives of the Quebec life sciences sector who actively and strategically contribute to the country's economy, they asked that the implementation of the PMPRB reform be suspended. A year later, on December 5th, 2022, new developments compel Montréal InVivo, Sherbrooke Innopole and BIOQuébec to reiterate this request. A new request for the postponement of the coming into force of new guidelines has therefore been formulated as part of the PMPRB's consultation process.
Read MoreDefence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful completion of all GLP studies related to its anti-cancer treatment, AccuTOX.
Read MoreDomain Therapeutics, a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announces the appointments of Professor Antoine Italiano and Professor John Stagg to its Scientific Advisory Board (SAB).
Read MoreMONTREAL (CANADA) – November 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD).
Read MoreOur executive director, Emmanuelle Toussaint, at BIOQuébec had the honor of participating to the “Rendez-Vous Politique de la Fédération des chambres de commerce du Québec (FCCQ)” with Canada’s Minister of Health, Jean-Yves Duclos
Read MoreQuebec is rich in innovative companies that strive to do things differently to bring our knowledge and skills to another level. We were delighted to honor our members Jenthera Therapeutics, Repare Therapeutics, Ventus Therapeutics, KisoJi Biotechnology, Valence Discovery and Modelis who all innovate in the field of life sciences for the development of new therapies.
Read MoreBIOquébec is proud to announce the winner of the Gala des Prix Innovation 2022 in the "Life Sciences" category: Innodal ! We are delighted to have such an innovative company among our members, that is innovating with a new generation of antimicrobials to improve food safety standards and meets the consumer’s demands. The ’’Prix Coup de Cœur ‘’ goes to Paperplane Therapeutics who designs therapeutic virtual reality video games aimed at improving pain and anxiety management in children undergoing various medical treatments or procedures. Congratulations to the finalists Ditch Labs and KAT Innovation.
Read MoreBROMONT, Québec--(BUSINESS WIRE)--Emmanuelle Toussaint, Executive Director at BIOQuébec, Québec's largest biotechnology and life sciences network, has been named one of Canada’s most inspiring climate leaders in the ‘Women in Energy Transformation Series’, an initiative by Women in Renewable Energy (WiRE), GLOBE Series and Pembina Institute. This award celebrates the most powerful women advancing Canada’s transition to a clean economy and identifies opportunities for more women to get involved.
Read MoreGSK today announced an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to help protect Canadian adults and children. The four-year agreement, spanning through March 2026, includes the supply of as many as 80 million doses of Arepanrix (adjuvanted pandemic influenza vaccine) in the event of an influenza pandemic(s) and a minimum of 4 million doses per year of Flulaval Tetra (seasonal influenza vaccine). Both vaccines will be supplied by GSK’s Sainte-Foy, Quebec facility. This agreement follows earlier agreements between the Government of Canada and GSK to supply both pandemic and seasonal influenza vaccines dating back to 2001.
Read MoreBROMONT, Quebec--(BUSINESS WIRE)--BIOQuébec’s Board of Directors is proud to announce the appointment of Emmanuelle Toussaint as Executive Director, effective immediately. “We are very pleased to have Emmanuelle join us as Executive Director. She is tremendously influential in the business community, and her diverse professional experiences, paired with her leadership, energy, and passion, will be greatly appreciated by BIOQuébec and our partners,” indicated Frédéric Leduc, President of the Board. “BIOQuébec has been supporting its members for over thirty years, and I firmly believe that Emmanuelle will take BIOQuébec to new heights.”
Read MoreThe BIOQuébec network consists of more than 100 life sciences industry members.Discover more about NMX Research and Solutions in its profile!
Read MoreA letter from BIOQuébec, Montréal InVivo, Life Sciences Ontario and LifeSciences BC, expressing our common vision of the important role of Intellectual Property (IP) protection in our knowledge driven economy.
Read MoreBIOQuébec welcomed the Québec government’s life sciences strategy which was unveiled earlier today, the contents of which will support the creation of value generated by the biotechnology and life sciences industry.
Read More
